246506-79-6Relevant articles and documents
Discovery of a novel chimeric ubenimex–gemcitabine with potent oral antitumor activity
Jiang, Yuqi,Hou, Jinning,Li, Xiaoyang,Huang, Yongxue,Wang, Xuejian,Wu, Jingde,Zhang, Jian,Xu, Wenfang,Zhang, Yingjie
, p. 5787 - 5795 (2016)
Herein, a novel mutual prodrug BC-A1 was discovered by integrating ubenimex and gemcitabine into one molecule. Biological characterization revealed that compound BC-A1 could maintain both the anti-CD13 activity of ubenimex and the cytotoxic activity of ge
Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy
Jiang, Yuqi,Li, Xiaoyang,Hou, Jinning,Huang, Yongxue,Wang, Xuejian,Jia, Yuping,Wang, Qingwei,Xu, Wenfang,Zhang, Jian,Zhang, Yingjie
, p. 334 - 347 (2017/12/07)
Previously a novel ubenimex-fluorouracil (5-FU) conjugate, BC-01 was identified and validated as a potent CD13 inhibitor with marked in vitro and in vivo antitumor potency. Herein, further structural modifications of the linker part of BC-01 was carried out to get more potent and stable ubenimex–fluorouracil conjugates. It was striking that most of these conjugates showed even more potent CD13 inhibitory activities than BC-01 and the approved CD13 inhibitor ubenimex. One representative compound 12a displayed significant in vitro anti-proliferation, pro-apoptosis, anti-metastasis, anti-angiogenesis and CD13+ cell elimination effects. In vitro stability and in vivo pharmacokinetic study revealed that compound 12a could release ubenimex and 5-FU slowly, which could act as a mutual prodrug of ubenimex and 5-FU. Compared with 5-FU or 5-FU plus ubenimex, 12a exhibited superior in vivo antitumor growth efficiency, even in our mice model of 5-FU-resistant liver cancer. Moreover, 12a exhibited more potent in vivo anti-metastasis and lifespan extension effects compared to the approved 5-FU prodrug capecitabine. Collectively, these results suggest that further optimization and evaluation of 12a as a promising anticancer candidate are warranted to develop effective therapeutic agents for human liver cancer.
MULTI-TARGETED UBENIMEX PRODRUG DERIVATIVE AND PREPARATION METHOD AND USE THEREOF
-
Paragraph 0065, (2015/12/08)
The present invention relates to the design, synthesis, and biological study of multi-targeted Ubenimex pro-drug derivative. More particularly, provided in the present invention is a compound as shown by general structural formula (I) (wherein the definit
Application of acyl cyanophosphorane methodology to the synthesis of protease inhibitors: Poststatin, eurystatin, phebestin, probestin and bestatin
Wasserman, Harry H.,Petersen, Anders K.,Xia, Mingde
, p. 6771 - 6784 (2007/10/03)
Full details are given for the syntheses of the protease inhibitors, poststatin and eurystatin by the acyl cyanophosphorane coupling procedure used for the formation of α-keto amides. We have also extended this methodology to the syntheses of the related α-hydroxy amide natural products, phebestin, probestin and bestatin. The key step in the latter synthetic sequences involved diastereomeric selectivity in the reduction of the α-keto precursor to the corresponding α-hydroxy amide by the use of zinc borohydride.
New stereoselective synthesis of the peptidic aminopeptidase inhibitors bestatin, phebestin and probestin
Righi, Giuliana,D'Achille, Claudia,Pescatore, Giovanna,Bonini, Carlo
, p. 6999 - 7002 (2007/10/03)
Peptidic aminopeptidase inhibitors, bestatin, phebestin and probestin have been prepared by stereo- and regiocontrolled reactions from a common α,β-epoxy ester precursor.
Synthesis of the peptidic α-hydroxy amides phebestin, probestin, and bestatin from α-keto amide precursors
Wasserman, Harry H.,Xia, Mingde,Petersen, Anders K.,Jorgensen, Michael R.,Curtis, Erin A.
, p. 6163 - 6166 (2007/10/03)
Aminopeptidase inhibitors, phebestin, probestin and bestatin have been prepared by stereospecific reduction of α-keto amide precursors using zinc borohydride.
